Evidence map›Paper›PMID 42348662›Full record

ArticleHuman vaccines & immunotherapeutics2026

Reduced T cell epitope cross-conservation and immunogenic potential is associated with emergence of a dominant influenza subclade K in 2025.

Andres H Gutierrez, Jacob Tivin, Ben Gabriel, Anne S De Groot

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Andres H GutierrezSpecial Scientific Projects, EpiVax, Inc., Providence, RI, USA.ORCID 0000-0002-6127-8327
Jacob TivinSpecial Scientific Projects, EpiVax, Inc., Providence, RI, USA.
Ben GabrielSpecial Scientific Projects, EpiVax, Inc., Providence, RI, USA.ORCID 0000-0003-0762-9082
Anne S De GrootSpecial Scientific Projects, EpiVax, Inc., Providence, RI, USA.ORCID 0000-0001-5911-1459

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Subclade K is a newly emergent influenza A/H3N2 strain that became the dominant strain circulating globally; more than 90% of influenza A virus (IAV) cases in 2025-26 were subclade K. While seasonal vaccines elicited measurable cross-reactive hemagglutination inhibition (HI) and neutralizing antibody responses against the new strain were deemed to be protective, T cells contribute substantially to protection against infection and severe disease. T cell epitopes that are conserved between vaccine strains and circulating strains may have a protective effect. We hypothesized that mutations in the HA antigen introduced by viral evolution resulted in the loss of some cross-conserved T cell epitopes and that this loss may have contributed to the emergence of subclade K. Using a new immunoinformatics tool, EpiCC, we assessed T cell epitope cross-conservation between subclade K, other circulating H3N2 strains, and the most recent seasonal vaccine strains. Evaluation of 706 H3N2 HA sequences demonstrated a 10% reduction in cross-conserved T cell epitope content between seasonal vaccines, circulating strains and subclade K. Decreased cross-conservation may signal the emergence of new flu strains. Proactive analysis of cross-conserved T cell epitopes may improve vaccine selection. Loss of T cell epitopes could also reduce the efficacy of new subclade K influenza vaccines in fall 2026.

Indexed as

Epitopes, T-LymphocyteInfluenza A Virus, H3N2 SubtypeInfluenza, HumanCross ReactionsHemagglutinin Glycoproteins, Influenza VirusHumansInfluenza VaccinesEpitopes, T-LymphocyteHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesEpiCCimmune escapeInfluenzaT-cell epitopeT cell immunityviral evolution

Identifiers

PMID42348662
PMCPMC13313233

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.